This diversity of functionally distinct proteins, all of which are involved in MDR development, encourages us to look at NRF2 as a potential target for modulation, with the goal of sensitizing cancer cells to chemotherapy [2,7,19]. This evidence concerns the gene NFE2L2 and cancer.